Tetravalent DNA vaccine product as a vaccine candidate against dengue

Kevin R. Porter, Nimfa Teneza-Mora, Kanakatte Raviprakash

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Dengue is the most important arbovirus worldwide and is the virus that causes dengue fever and the more severe dengue hemorrhagic fever. There are four serotypes of dengue with each possessing the ability to cause disease. Developing a preventive vaccine is the most efficient and effective way to prevent these diseases, and because immunity to one serotype does not protect against the other serotypes, a vaccine must provide tetravalent protection. We used DNA immunization as a platform to develop a tetravalent vaccine. In this chapter, we describe the laboratory, regulatory, and clinical methodology for evaluating a candidate tetravalent vaccine in a Phase 1 clinical trial.

Original languageEnglish
Pages (from-to)283-295
Number of pages13
JournalMethods in molecular biology (Clifton, N.J.)
StatePublished - 2014


  • Adjuvant
  • Clinical trial
  • DNA vaccine
  • Dengue
  • Tetravalent
  • Vaxfectin ®


Dive into the research topics of 'Tetravalent DNA vaccine product as a vaccine candidate against dengue'. Together they form a unique fingerprint.

Cite this